QGEN
QIAGEN NV
NYSE · Healthcare · Medical - Diagnostics & Research · NL
$43.33
−2.37%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$44.30
From 52W high−22.15%
Volume1.71M
Market cap$8.95B
P/E (TTM)22.2x
P/S (TTM)4.3x
Div yield6.37%
Key dataSep 18, 2026
Open
$44.30
From 52W high
−22.15%
Volume
1.71M
Market cap
$8.95B
ValuationView details →
P/E (Fwd)
17.4x
EV/EBITDA
13.3x
P/E (TTM)
22.2x
RSI (14)
57.0
MomentumView details →
1D Return
−2.37%
YTD Return
−6.97%
SummaryUpdated Jun 1, 2026
QIAGEN N.V. (NASDAQ:QGEN) is a Netherlands-based multinational biotechnology company founded in 1986 that specializes in molecular diagnostics and life sciences research technologies. Originally established as a spin-off from the University of Düsseldorf, QIAGEN went public in 1996 and has grown through both organic expansion and strategic acquisitions to become a leading provider of sample preparation and molecular testing solutions. The company serves customers across molecular diagnostics, academic research, pharmaceutical development, and applied testing markets worldwide, with operations spanning over 35 countries and headquarters in Venlo, the Netherlands.
Similar companies
Latest newsMore news →
TPG and Bain Capital emerged as potential bidders for Qiagen, with KKR, EQT and Advent also reportedly interested in acquiring the Dutch molecular diagnostics company, according to Manager Magazin.3d agoQIAGEN N.V. announced the commercial launch of QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction, building on its QIAsymphony platform with over 3,300 cumulative placements worldwide.24d ago